This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Michael M. Safani, PharmD; David S. Tatro, PharmD; Peter Rudd, MD
Stanford, Calif

Arch Intern Med. 1982;142(4):838-839.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—We would like to report a case of fulminant hepatitis that was probably caused by propylthiouracil therapy. To our knowledge, this is the first such fatal case reported, although death due to agranulocytosis after propylthiouracil administration has been previously described.¹

Report of a Case.

—A 20-year-old woman was in excellent health until the diagnosis of Graves' disease was made. Her condition was characterized by profound exophthalmos, a triiodothyronine uptake of 64% (normal, 22% to 34%), a thryoxine radioimmunoassay of 28.5 µg/dL (normal, 5 to 11 µg/dL), and a free thyroxine index of 18.2 (normal, 0.8 to 2.3). Subsequently, administration of 100 mg of propylthiouracil three times a day was instituted. Two weeks after therapy began, she experienced malaise and jaundice associated with abnormal findings from liver function tests. Laboratory values were as follows: SGOT, 750 IU/L (normal, 0 to 41 IU/L); alkaline phosphatase, 248 IU/L (normal, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?